CME Presentations

AMD


Presentations


Speakers


CME Information

PIM Logo PQH Logo

Maintaining Vascular Stability while Reducing Age-related Macular Degeneration Treatment Burden: The Promise of Emerging Patient-centered Approaches

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the American Macular Degeneration Foundation (AMDF).

ACKNOWLEDGEMENT

Supported by an educational grant from Genentech, a member of the Roche Group.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Monday, April 11 from 6:00 – 7:00pm ET

Enduring Material

The enduring material will be available from April 11, 2022 to May 4, 2023.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Recognize the burden that wet AMD and treatment with current anti-VEGF pose to patients and caregivers, including the need for frequent intravitreal injections and the potential for adverse effects of consecutive injections (i.e., fibrosis, scarring)
  • Summarize the most current safety and efficacy data on new and emerging therapeutic options to maintain vascular stability and reduce treatment burden, including dual acting anti-VEGF and Ang-2
  • Discuss how emerging delivery systems may reduce the need for frequent injections, while maintaining or improving visual acuity and reducing fluctuations in macula thickness
  • Highlight surgical steps that help reduce risk of complications during device insertion and refill of the port delivery system with ranibizumab

TARGET AUDIENCE

The intended audience for this activity are ophthalmologists, optometrists, and specialty NPs and nurses who diagnose and treat AMD.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com and www.ClinicalSeriesLive.com.To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Margaret A. Chang, MD, MS, FASRS
Senior Partner
Retinal Consultants, Sacramento
Employee/Owner: Retinal Consultants of America
Grant/Research Support: Allergan, Genentech, Mylan, Novartis, NGM, Opthea, Ophthotech, Regeneron, RegenXBio
Consultant/Advisory Board: Genentech, RegenXBio
Dante J. Pieramici, MD
Director, California Retina Research Foundation
Partner, California Retina Consultants
Member, Retina Consultants of America
Grant/Research Support: Adverum, Annexion, Apellis, Genentech, Gyroscope, Iveric, NGM, Ocular Therapeutix, Ophthea, Regeneron, Regenx Bio, Stealth, Unity, 4DMT
Consultant/Advisory Board: Adverum, Gemini, Genentech, Iveric, NGM, Regeneron, Regenx bio, Unity
Non-Mutual funds Stock Ownership/Stock options: Gemini

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Carole Drexel
Medical Director
PlatformQ Health Education, LLC
None
Eve Wilson
Medical Director
PlatformQ Health Education, LLC
None


The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive.com at 877-394-1306 or at Support@ClinicalSeriesLive.com.
PIM Logo PQH Logo

The Role of the Optometrist in Elevating AMD Care and Facilitating Early Access to Breakthrough, Patient-centered Therapy for AMD: What Patients Tell Us

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the American Macular Degeneration Foundation (AMDF).

ACKNOWLEDGEMENT

Supported by an educational grant from Genentech, a member of the Roche Group.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COUNCIL ON OPTOMETRIC PRACTITIONER EDUCATION (COPE) CREDIT STATEMENT – Interactive Distance Learning Course

This activity, COPE Activity Number 123356 is accredited by COPE for continuing education for optometrists. This course is COPE approved for 1 hour of CE credit. Course ID is 76872. Please check your state licensing board to see if this approval counts toward your CE requirement for relicensure.

COUNCIL ON OPTOMETRIC PRACTITIONER EDUCATION (COPE) CREDIT STATEMENT – Enduring Distance Learning Course

This activity, COPE Activity Number 123357 is accredited by COPE for continuing education for optometrists. This course is COPE approved for 1 hour of CE credit. Course ID is 76873. Please check your state licensing board to see if this approval counts toward your CE requirement for relicensure.

DATE OF RELEASE/EXPIRATION

Live Activity

Wednesday, May 4, 2022 from 6:00 – 7:00pm ET

Enduring Material

The enduring material will be available from May 4, 2022 to May 4, 2023.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Summarize the rationale and urgent need for earlier screening and diagnosis of patients with AMD and collaboration with ophthalmologists to ensure early treatment
  • Explain the benefits of new and emerging technologies to detect AMD earlier, in the subclinical stage, to enhance access to effective treatment
  • Describe collaborative multidisciplinary, patient-centered strategies to ensure that patients with wet AMD get an early diagnosis and early initiation of treatment
  • Discuss the promise of the growing pipeline for the management of AMD in maintaining or improving visual acuity and reducing the need for frequent injection, while enhancing vascular stability

TARGET AUDIENCE

The intended audience for this activity are ophthalmologists, optometrists, and specialty NPs and nurses who diagnose and treat AMD.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.ClinicalSeriesLive.com.To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Dorene Beavers
Patient with AMD
Nothing to disclose
Arshad M. Khanani, MD, MA
Vitreo-Retinal Diseases and Surgery
Managing Partner, Director of Clinical Research, Director of Fellowship - Sierra Eye Associates
Clinical Associate Professor - University of Nevada, Reno
Grant/Research Support: Adverum, Apellis, Asclepix, Chengdu Kanghong, 4DMT, Gemini, Genentech, Graybug Vision, Gyroscope, Iveric Bio, Janssen, Kodiak, Neurotech, NGM Bio, Ocular Therapeutix, Oculis, Opthea, Oxurion, Novartis, Recens Medical, Regenxbio, Roche, Unity Bio
Speakers Bureau/Honoraria for non-CME: Allergan, Genentech, Novartis
Consultant/Advisory Board: Adverum, Aerpio, Alimera, Allergan, Apellis, Asclepix, Aviceda, Bausch and Lomb, Broadwing Bio, Chengdu Kanghong, Cholgene, 4DMT, Dutch Ophthalmic Research Center, Gemini, Genentech, Glaukos, Graybug, Gyroscope, Iveric Bio, Janssen, Kato Pharma, Kodiak, Oculis, Opthea, Oxurion, Novartis, Polyphotonix, Recens Medical, Regeneron, Retrotope, Regenxbio, Roche, Surrozen, Thea, Unity Bio
Non-Mutual funds Stock Ownership/Stock options: Aviceda, Recens Medical, Retrotope, Polyphotonix
Matthew Levine, MA
Grants, Advocacy and Partnerships Director
American Macular Degeneration Foundation
Consultant/Advisory Board: Novartis
Pamela A. Lowe, OD, FAAO, Dipl. ABO
Past Chair, AOA Contact Lens Cornea Section
Diplomate, American Board of Optometry
Vision Source Medical Director, Chicago
Director, Professional Eye Care Center, Inc.
Speakers Bureau/Honoraria for non-CME: Alcon, Essilor, Maculogix
Consultant/Advisory Board: Alcon, Essilor, Maculogix, MyGenetics

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Carole Drexel
Medical Director
PlatformQ Health Education, LLC
None
Eve Wilson
Medical Director
PlatformQ Health Education, LLC
None


The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive.com at 877-394-1306 or at Support@ClinicalSeriesLive.com.